Indivior PLC
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark Crossley
- Full Time Employees
- 1,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 10710 Midlothian Turnpike North Chesterfield VA United States of America 23235
- IPO Date
- Dec 26, 2014
- Website
- indivior.com
- Similar Companies
- Business
- Indivior PLC is a global pharmaceutical company that develops, manufactures and commercializes buprenorphine-based prescription drugs and other medications for the treatment of opioid use disorder and serious mental illnesses; its core products include SUBLOCADE (buprenorphine extended-release injection), SUBOXONE (buprenorphine/naloxone sublingual film and tablet), OPVEE (nalmefene nasal spray for opioid overdose reversal), PERSERIS (risperidone extended-release injection for schizophrenia), and SUBUTEX (buprenorphine sublingual tablet and prolonged-release injection), with product availability in over 30 countries including the United States, Canada, Australia, France, Germany and select rest-of-world markets. Founded in 1994 as the buprenorphine division of Reckitt Benckiser and spun off as an independent public limited company incorporated in 2014, Indivior maintains its registered office at 234 Bath Road, Slough, Berkshire, United Kingdom, and operational headquarters in North Chesterfield, Virginia, USA. The company primarily serves healthcare providers, patients with substance use disorders, and criminal justice systems, generating the majority of its revenue from the United States followed by the United Kingdom and other international markets. In recent developments, Indivior completed the cancellation of its secondary listing on the London Stock Exchange in July 2025 while retaining its primary Nasdaq listing, announced plans in October 2025 to redomicile from the UK to the US via a scheme of arrangement establishing a new US parent company Indivior Pharmaceuticals Inc., initiated organizational simplification in Q3 2025 including headcount reductions, closure of three R&D and medical affairs locations, discontinuation of OPVEE commercial support, and exits from several non-US markets such as the UK, Ireland, Sweden, Israel, Finland and Italy to achieve at least $150 million in annual operating expense savings starting 2026, appointed Joseph Ciaffoni as Chief Executive Officer in February 2025, and received FDA approval for SUBLOCADE label changes while raising FY2025 revenue guidance to $1.18-1.22 billion.
Indivior PLC Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights - INDV
FINAL REMINDER INDV DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Indivior PLC Investors to Participate in the Class Action Lawsuit!
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Indivior PLC(INDV) Shareholders
INDV Deadline: Rosen Law Firm Urges Indivior PLC (INDV) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Class Action Filed Against Indivior PLC (INDV) Seeking Recovery for Investors - Contact Levi & Korsinsky
INDV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Indivior PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Indivior PLC(INDV) Shareholders
Indivior PLC Is Being Sued For Violating Securities Laws And Affected Investors Are Encouraged To Lend A Hand To The Schall Law Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Indivior PLC of Class Action Lawsuit and Upcoming Deadlines – INDV
Shareholders that lost money on Indivior PLC(INDV) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Investors who lost money on Indivior PLC(INDV) should contact Levi & Korsinsky about pending Class Action - INDV
INDV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Indivior PLC Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
The Schall Law Firm Invites Stockholder Participation In A Securities Fraud Case Against Indivior PLC
INDV Deadline: INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 1, 2024 in Indivior Lawsuit – INDV
Class Action Filed Against Indivior PLC (INDV) - October 1, 2024 Deadline to Join – Contact Levi & Korsinsky
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit
Indivior PLC Is Being Sued For Violating Securities Laws And Investors Are Urged To Assist The Schall Law Firm
Class Action Filed Against Indivior PLC (INDV) Seeking Recovery for Investors - Contact Levi & Korsinsky
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Indivior PLC of Class Action Lawsuit and Upcoming Deadlines - INDV